GnRH Agonist Pretreatment Duration and Letrozole Supplementation in Frozen Embryo Transfer for Adenomyosis Patients

Launched by FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Jul 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the best way to prepare the uterus for frozen embryo transfer (FET) in women who have adenomyosis, a condition where the inner lining of the uterus grows into the muscle wall, which can affect pregnancy. Researchers want to find out if giving one or two doses of a hormone medicine called GnRH agonist before the embryo transfer helps improve the chances of having a baby. They are also testing whether adding another medicine called letrozole to the treatment makes a difference in success rates.

Women between 20 and 38 years old who have been diagnosed with adenomyosis through an ultrasound and are planning to have a frozen embryo transfer may be eligible to join. Participants will be randomly placed into one of four groups, each receiving different combinations of hormone treatments before the embryo transfer. The goal is to see which approach leads to more live births. Before starting, women will be carefully screened to make sure they meet the criteria and do not have other conditions that could affect the results. If you take part, you will have hormone treatments for up to two months before preparing your uterus for the embryo transfer in a controlled cycle. This study aims to help doctors choose the best treatment plan for women with adenomyosis who want to have a baby through frozen embryo transfer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Sonographically diagnosed adenomyosis via transvaginal ultrasound;
• • Candidates scheduled for frozen single blastocyst (Day5, Day6) transfer
• • Age 20-38 years
• • Previous embryo transfer attempts: ≤2 cycles
• Exclusion Criteria:
• • Patients diagnosed with Recurrent pregnancy loss, Autoimmune disorders (e.g., systemic lupus erythematosus), Uterine fibroids ≥5 cm, Cervical incompetence, Cesarean scar niche
• • History of Myomectomy and/or adenomyosis lesion excision, Cervical conization
• • Patients presenting with Congenital Müllerian anomalies (unicornuate uterus, septate uterus, etc.), Endometrial atypical hyperplasia, malignancy or defects
• • Sperm retrieval method: Micro-TESE (microdissection testicular sperm extraction)
• • Fertilization method: Rescue ICSI
• • Endometrial thickness \<7 mm, Intrauterine adhesions, Intrauterine fluid
• • Contraindications to exogenous hormone administration
• • Use of GnRH within 3 months prior to enrollment